about
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.New treatments for myelodysplastic syndromesSimilarities and differences between therapy-related and elderly acute myeloid leukemia.Outcome of therapy-related myeloid neoplasms treated with azacitidineWhy methylation is not a marker predictive of response to hypomethylating agents.Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.Clonal evolution in therapy-related neoplasms.Treatment of Low-Blast Count AML using Hypomethylating Agents.Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report.Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.Fanconi anemia gene variants in therapy-related myeloid neoplasms.SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian RegMutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.Epigenetic changes in therapy-related MDS/AML.SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome.Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-AzacytidineSomatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromesTherapy-related myeloid neoplasms: clinical perspectivesCeftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experienceMutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS)Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromesPrimary plasma cell leukemia followed by testicular plasmacytomaAzacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing scheduleThe BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromesRapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotinMethylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasmsCeftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current ExperiencesErythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromesFungaemia in haematological malignancies: SEIFEM-2015 surveyIn vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
P50
Q30240242-E313920F-30F4-4570-996C-0AC19313DE62Q33877952-AD88E31B-1812-41FF-9AAD-EEA1B50656D0Q34549290-B04C316A-B810-40BA-9C14-CA9D87455813Q35640731-BCB37081-937D-4611-9BF0-3E934A30C443Q36165737-AFA0FC8C-0F41-4627-9CE3-A8075F2AE908Q37676259-B704433F-9C8E-43B0-AA21-83E7ED4ACA5FQ38656591-57736FF2-5BCD-4B6C-B56B-47ECE1924DCCQ38860919-21B4E5E4-0958-4FC1-8373-9DCD6113D6CBQ39026726-E0CE100E-7D7B-4CD5-A256-E1EDCCCB61D2Q39429687-601EB196-E2BF-4990-940D-C4991F170585Q40125779-8A8037B8-A820-4A73-AAE3-A5CAF4467FDDQ40788034-AB10210C-167B-47CD-A9E0-DC58BA798812Q40793299-1779D2D1-DA98-4572-BD62-9E8D574B5859Q40896172-301B594D-B8EF-470F-A2B6-04B5A4004DBFQ41237697-A04CBAD3-A4EA-42DE-BED5-575FF3388543Q42421841-0314D4CC-01F0-4C39-BDF9-761D23631AFEQ43135315-06904775-2442-40B6-96B2-5BCD4F52B92EQ43584950-FF57165F-C199-4C33-9019-A29DD0AF4FAFQ44023853-890D4CCF-FC23-4399-8DA5-98507AE9DB5AQ44059578-B5E937C8-F49B-435E-9F94-E1BCE5C85A01Q45358400-7F7B2C6F-1FF5-41C2-A657-8A2F12BAB76AQ46589950-8D3D2608-29A5-4E4E-A216-0E5D9629A9F8Q47235713-C666E9F8-DFDF-4E6A-8E25-488F3ECBA289Q48192522-3B5F4FDE-4012-41C9-AEFA-9E27E249BEC2Q53293408-1CD06722-7B7B-4A66-980F-1BDC2930A016Q56773016-FF26A05F-9A74-4597-91CB-0A67EF1A4471Q57022496-3575CA1E-92AD-469F-903D-8FE922B4DD4AQ57074546-58CCFEA1-076E-49EA-A8FD-671D4947E3BEQ58541880-665666E6-8366-4233-A36B-41B68459E695Q58577048-F39368F6-8651-4893-8FED-A17A8F7DDF79Q82699607-EAD86C2B-3D65-4824-8466-D073C819A0E0Q83181124-F0C6E366-7733-47B4-8DDB-3B234D12D8D2Q84929311-FEFB7943-26BD-406A-B14F-1E0C4AD04D78Q85946478-670C18F5-5229-469D-926C-3A637D6FC0C8Q86003237-BA6113CD-DCF1-48F8-AD6B-F58031D7EF3AQ87434824-2A0EABD8-901C-4C96-85BD-482B699FD39AQ89578268-4EC6B926-4ED4-43AB-A1FD-5171CD15449AQ90366666-4E4DB055-88C9-4F85-93B5-DF2660D2BD72Q91419110-0F9BC350-3D11-49E9-BD01-3CEDF1651310Q91735868-102EF680-1ABF-498E-91A7-01E22792A10A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Marianna Criscuolo
@en
Marianna Criscuolo
@nl
type
label
Marianna Criscuolo
@en
Marianna Criscuolo
@nl
prefLabel
Marianna Criscuolo
@en
Marianna Criscuolo
@nl
P31
P496
0000-0001-5661-2338